IPO registrations (S-1, F-1) · Registrants
Orchard Therapeutics plc
- SEC CIK
- 1748907 · filings on EDGAR ↗
- Former names
- Orchard Rx Ltd (2018–2018)
- Registration
- Form F-1, first filed 2018-10-04, last 2019-06-03; 2 initial registrations, 2 amendments
- Outcome
- Final prospectus filed 2018-10-31; declared effective 2018-10-30
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- X0
- Business address
- 245 HAMMERSMITH ROAD, 3RD FLOOR, London, X0 W6 8PW
- EDGAR entity type
- operating
- Insiders and CEO pay
- Orchard Therapeutics plc on the corporate pages
Offering terms
- Final price
- $14.00 per ADS (424B4 filed 2018-10-31, an initial public offering)
- Shares sold
- 14,285,715
- Gross proceeds
- $200,000,010 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ORTX
- Lead underwriters
- J.P. Morgan (5,000,000 shares); Goldman Sachs (4,285,715 shares); Cowen (3,714,286 shares)
- Syndicate
- Wedbush Securities (1,285,714)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Orchard Therapeutics plc EXACT (CIK (EXACT))
- SEC filer: Orchard Therapeutics plc EXACT (CIK (EXACT))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2018-10-04 | F-1 | F-1 (foreign registration) | Orchard Rx Ltd | 0001193125-18-293354 ↗ |
| 2018-10-23 | F-1/A | F-1/A (amendment) | Orchard Rx Ltd | 0001193125-18-304629 ↗ |
| 2018-10-26 | F-1/A | F-1/A (amendment) | Orchard Rx Ltd | 0001193125-18-308645 ↗ |
| 2018-10-30 | F-1MEF | F-1MEF (added securities) | Orchard Therapeutics plc | 0001193125-18-312543 ↗ |
| 2018-10-30 | EFFECT | EFFECT (declared effective) | Orchard Therapeutics plc | 9999999995-18-002757 ↗ |
| 2018-10-30 | EFFECT | EFFECT (declared effective) | Orchard Therapeutics plc | 9999999995-18-002761 ↗ |
| 2018-10-31 | 424B4 | 424B4 (final prospectus) | Orchard Therapeutics plc | 0001193125-18-313993 ↗ |
| 2019-06-03 | F-1 | F-1 (foreign registration) | Orchard Therapeutics plc | 0001193125-19-164149 ↗ |
| 2019-06-05 | EFFECT | EFFECT (declared effective) | Orchard Therapeutics plc | 9999999995-19-001278 ↗ |
| 2019-06-06 | 424B4 | 424B4 (final prospectus) | Orchard Therapeutics plc | 0001193125-19-167219 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-10-26 | F-1/A | registration statement | 100,000 | - | 0 | primary document; shares headline | document ↗ | |||
| 2018-10-31 | 424B4 | final prospectus | $14.00 | 14,285,715 | $200,000,010 | Nasdaq ORTX | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Beck Joanne T. | Director | 6 | 2020–2024 | ||
| Curnutte John T | Director | 6 | 2020–2024 | ||
| Dunoyer Marc | Director | 6 | 2020–2024 | ||
| Ellis Jon | Director | 1 | 2020 | ||
| FMR LLC | Other; TenPercentOwnerOther | 5 | 2020–2021 | ||
| Gaspar Bobby | Director,Officer | Chief Executive Officer; See Remarks | 11 | 2020–2024 | |
| GERAGHTY JAMES A | Director | 6 | 2020–2024 | ||
| GLAXOSMITHKLINE PLC | Director,TenPercentOwner | 1 | 2020 | ||
| Rothera Mark | Director,Officer | See Remarks | 1 | 2020 | |
| Rowland Charles A Jr | Director | 6 | 2020–2024 | ||
| Secor Alicia | Director | 6 | 2020–2024 | ||
| THOMAS FRANK E | Officer | See Remarks | 14 | 2020–2024 | |
| Altschuler Steven | Director | 7 | 2020–2024 | ||
| Kolchinsky Peter | Director,TenPercentOwner; TenPercentOwner | 3 | 2020–2021 | ||
| RA Capital Healthcare Fund LP | Director,TenPercentOwner; TenPercentOwner | 3 | 2020–2021 | ||
| RA CAPITAL MANAGEMENT, L.P. | Director,TenPercentOwner; TenPercentOwner | 3 | 2020–2021 | ||
| Shah Rajeev M. | Director,TenPercentOwner; TenPercentOwner | 3 | 2020–2021 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2023-03-23 | Orchard Therapeutics plc | Biotechnology | Indefinite | $34,000,140 | 7 | 1 |
| 2021-02-24 | Orchard Therapeutics plc | Biotechnology | $149,999,996 | $149,999,996 | 24 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Orchard Therapeutics plc | Form D private offerings | CIK (EXACT) | |
| SEC filer | Orchard Therapeutics plc | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), X0 first:
- Abcam plc X0
- Immunocore Holdings plc X0
- Autolus Therapeutics plc X0
- Freeline Therapeutics Holdings plc X0
- Achilles Therapeutics plc X0
- Gyroscope Therapeutics Holdings plc X0
- OKYO Pharma Ltd X0
- Exscientia plc X0
- TC BioPharm (Holdings) plc X0
- BioNTech SE 2M
In other datasets, the same topic (Health) in X0:
- Form D issuer: Abcam plc (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health